USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Bioprojet

USPTO PatentsView assignee record - 11 granted patents across 4 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Bioprojet ranks #23,984 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 4 technology areas.

#23,984
of 49,997 US assignees by volume
Top 47%
by Innovation Score (36.2/100)
12.0
avg claims per patent
+20%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23984 · Foreign Corporation #23,984 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-UP · BOOK-FULL

  • GRANTS-MICRO 11 grants
  • MID-PACK #23,984/49,997
  • PHOTO-FINISH BIO ON S P A
  • CPC-NARROW A61P · 4 areas
  • INNOV-THIN 36.2/100
  • CLAIMS-RICH 12.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-UP +20% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: BIO ON S.P.A. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Bioprojet’s 36.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Bioprojet

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Bioprojet's Innovation Score is 36.2/100 (top 47% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Bioprojet?

Each dot is one of Bioprojet’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Bioprojet’s own 12.0 claims/patent is at or below the 17.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Bioprojet vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 10.910.91111.1 10152025 Granted patents (volume) Avg claims / patent BIO ON S.P.A. - 11, 15.91BIO ON S P ABiomea Fusion, Inc. - 11, 20.82Biomea FusionBiomeme Inc. - 11, 20.55BiomemeBiopath Automation, LLC - 11, 12.64Biopath AutomationBiosafe SA - 11, 17.18BiosafeBiothera Inc. - 11, 19.36BiotheraBiothread LLC - 11, 22.73BiothreadBiovision Technologies, LLC - 11, 15.64BiovisionBioprojet - 11, 12Bioprojet
Bioprojet vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Bioprojet's grants concentrate

Bioprojet is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (4 grants) versus a trough of 1 in 2015. By volume, Bioprojet sits between BIO ON S.P.A. and Biovision Technologies, LLC.

Bioprojet's three-year grant acceleration

Bioprojet shows 4 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Bioprojet's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Bioprojet holds 11 patents at rank #23,964, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Bioprojet

By rank, the assignees closest to #23,964 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Bioprojet's primary technology class.

Bioprojet's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 20152016202120222024 2
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Bioprojet patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 9.1%
2016 4 36.4%
2021 2 18.2%
2022 2 18.2%
2024 2 18.2%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Bioprojet's patent record in context - here's where to go next.

  • Bioprojet's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #23,984 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Bioprojet against BIO ON S.P.A., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 36.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.